格隆汇1月28日丨塞力医疗(603716.SH)在投资者互动平台表示，目前公司暂无尼帕病毒病原学检测试剂/ 仪器或治疗药物储备，也暂无相关产品代理。我们的布局重点在"高危急性感染的早期识别与预警"能 力：基于战略投资并引进的Inflammatix TriVerity急性感染与脓毒症检测，可在症状极早期通过mRNA转 录组信号实现感染类型判断（病毒/细菌/非感染）及重症/脓毒症风险分层。对尼帕这类疑似病例， TriVerity可作为急诊/发热门诊的早期预警与分诊升级工具，提示更高等级隔离与监护、支持更快启动确 诊检测与救治流程，最终确诊仍需病原学检测配合。 ...

Core Viewpoint - The company DaAn Gene has developed a comprehensive solution for Nipah virus pathogen detection, which can assist customs and disease control agencies in precise prevention and control efforts [2] Group 1: Product Offerings - DaAn Gene has recently launched the domestic small-scale rapid gene sequencer DAseq-60, which can be integrated with the Geno24 automated library preparation instrument, the viral whole genome detection reagent kit, and the pathogen intelligent analysis system to provide a complete clinical solution [2] - The second-generation sequencing solution enables the completion of whole genome sequencing of the Nipah virus, fulfilling various analytical needs such as mutation monitoring, typing tracing, and phylogenetic tree analysis, compared to traditional detection methods [2]

（文章来源：每日经济新闻） 每经AI快讯，1月28日，三友医疗公告，经公司财务部门初步测算，公司预计2025年年度实现归属于上 市公司股东的净利润为5600万元到7280万元，同比增加388.29%到534.78%。 ...

Core Viewpoint - The company expects a significant increase in net profit for 2025, projecting a range of 56 million to 72.8 million yuan, representing a year-on-year growth of 388.29% to 534.78% [1] Financial Projections - The projected net profit attributable to shareholders for 2025 is between 56 million and 72.8 million yuan, with a non-GAAP net profit forecasted at 43 million to 61 million yuan, indicating a turnaround from losses [1] - The company anticipates a total of approximately 30 million yuan in asset impairment and credit impairment losses for the year [1] Business Strategy and Growth - The company plans to leverage its innovative therapies and expand its product line to enhance sales and market penetration, particularly in the orthopedic sector, where it is a leading player [1] - The ultrasound knife business is expected to see rapid growth in both sales and net profit in 2025 [1] - The international business, particularly through its subsidiary Implanet, is projected to achieve revenue of 1,247.39 million euros, a year-on-year increase of 32.62%, with the U.S. market showing a remarkable growth of 49.30% [1] Product Development and Market Expansion - The company aims to expedite the registration of innovative products such as the intelligent surgical robot and porous polyether ether ketone interbody fusion device in China [1] - There is a focus on increasing the penetration of the ultrasound knife business and promoting integrated product series in various surgical departments [1] - The company is committed to advancing its strategic business layout and ensuring the timely approval of its innovative products in the U.S. market by 2026 [1] Equity Incentive Plan - The company will introduce an equity incentive plan in 2025, with an estimated share-based payment expense of approximately 8.4 million yuan for the year [1]

中国经济网北京1月28日讯 三大股指涨跌不一，创指午后回落翻绿。截至收盘，上证指数报4151.24点，涨幅0.27%，成交额13655.26亿元；深证成指报 14342.89点，涨幅0.09%，成交额15998.84亿元；创业板指报3323.56点，跌幅0.57%，成交额7441.76亿元。 板块方面，贵金属、油气开采及服务、工业金属等板块涨幅居前，光伏设备、医疗服务、医疗器械等板块跌幅居前。 | 序号 | 板块 | 涨跌幅(%)▼ | | 总成交量 (万手) ▼ 总成交额 (亿元) ▼ | 净流入 (亿元) ▼ | 上涨家数 | 下跌多 | | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 音等屋 | 10.74 | 1387.18 | 453.36 | 21.93 | 11 | o | | 2 | 油气开采及服 | 7.54 | 3076.39 | 254.01 | 24.76 | 20 | o | | | ਡੇ | | | | | | | | 3 | 工亦等選 | 6.24 | 9201.81 | 1552.80 | 70.55 | ਦੇਤੋ ...

Group 1 - The core point of the news is that Aomei Medical's stock price dropped by 5% to 12.16 yuan per share, with a trading volume of 193 million yuan and a turnover rate of 3.47%, resulting in a total market capitalization of 7.701 billion yuan [1] - Aomei Medical, established on July 24, 2002, and listed on March 11, 2019, specializes in the research, production, and sales of disposable medical consumables, particularly medical dressings [1] - The main revenue composition of Aomei Medical includes surgical and wound care at 79.19%, other categories at 6.62%, infection protection at 5.05%, advanced dressings at 4.68%, and hygiene care at 4.46% [1] Group 2 - Among the top ten circulating shareholders of Aomei Medical, a fund under Yongying Fund is included, and the Medical Device ETF (159883) entered the top ten shareholders in the third quarter, holding 1.5656 million shares, which accounts for 0.35% of the circulating shares [2] - The Medical Device ETF (159883) was established on April 22, 2021, with a latest scale of 3.677 billion yuan, and has achieved a year-to-date return of 8.42%, ranking 1994 out of 5549 in its category [2] - The fund has a one-year return of 14.06%, ranking 3672 out of 4285, and has experienced a cumulative loss of 47.1% since its inception [2] Group 3 - The fund manager of the Medical Device ETF (159883) is Shu Kefa, who has been in the position for 2 years and 169 days, managing a total fund size of 5.205 billion yuan [3] - During the tenure of the fund manager, the best fund return was 103.17%, while the worst return was -30.27% [3]

盘面上，现货黄金首次站上5200美元，贵金属、黄金板块继续爆发，中金黄金、赤峰黄金等十余股涨停；有色金属板块掀涨停潮，白银有色、常铝股份等多 股涨停；转基因板块拉升，农发种业涨停；汽车拆解板块走高，飞南资源20CM涨停；钛白粉、煤化工及磷化工等板块涨幅居前。另外，生物疫苗、痘病毒 防治板块下挫，百普赛斯跌逾10%；医疗器械板块走低，之江生物跌逾8%；光伏社板块走弱，高测股份跌逾8%；航天航空、装修装饰及CRO等板块跌幅居 前。(格隆汇) | 上证指数 | 深证成指 | 北证5( | | --- | --- | --- | | 4151.24 | 14342.89 | 1562.4 | | +11.33 +0.27% +12.99 +0.09% -2.49 -0 | | | | 科创50 | 创业板指 | 万得全/ | | 1554.80 | 3323.56 | 6863.2 | | -1.17 -0.08% -19.04 -0.57% +7.43 +0 | | | | 沪深300 | 中证500 | 中证A5( | | 4717.99 | 8601.16 | 5951.1 | | +12.30 +0.26% ...

（文章来源：每日经济新闻） 1月28日医疗器械板块震荡调整，之江生物、万孚生物、迪安诊断、圣湘生物、三友医疗跌幅超5%，医疗器械ETF（562600）下跌2.18%。 从指数月线位置来看，医疗器械指数当前处在上一波熊牛转换起点附近，价格仍属相对低位，建议逢低关注。 ...

Core Viewpoint - Yongsheng Medical (01612) has experienced a stock price increase of over 9% following the announcement of a positive earnings forecast, with shares trading at HKD 0.94 and a transaction volume of HKD 5.3888 million [1] Group 1: Earnings Forecast - The company anticipates an unaudited consolidated profit attributable to shareholders of no less than HKD 100 million for the fiscal year ending December 31, 2025 [1] - For the fiscal year ending December 31, 2024, the audited profit attributable to shareholders is expected to be approximately HKD 69.2 million [1] Group 2: Reasons for Growth - The board attributes the significant increase in revenue to strengthened relationships with a major customer in the imaging disposable products segment and the expansion of business scale [1] - The company has achieved better economies of scale by enhancing capacity utilization and operational efficiency, leading to improved gross profit margins [1]

每经AI快讯，1月28日，据国家药监局官网消息，为满足监管急需，助推采用脑机接口技术的医疗器械 高质量发展，经研究，国家药监局批准《采用脑机接口技术的医疗器械范式设计与应用规范运动功能重 建》《采用脑机接口技术的医疗器械侵入式设备可靠性验证方法》等2项医疗器械行业标准制修订项目 立项。 ...